Summer Update 2016
The latter part of spring has certainly been hot, and it looks as though summer is going to be the same! Are you a teacher or member of another profession that has summers off? Due to patients' travels, Dr. Keenan's and Autumn's schedules tend to be a little lighter during the summer months. Call today to schedule an appointment before the hustle and bustle of the working world resumes. You can expect personalized attention and timely return appointments. (865)777-0088.
New Financing Options Available!
While we don't typically recommend financing your infertility treatments, we realize that it is sometimes the best option for a particular couple. Our practice manager, Juliana Stanley, has new options, as well as certain infertility grant information, that may help you to plan your treatments in a timely manner. Please give her a call at (865)777-0088, extension 2.
Change in Office Hours for Thursdays, September 1st and 8th
Our office hours on Thursdays, September 1st and 8th will be 8:00 AM to 4:30 PM. We WILL NOT be open until 6:00 PM as we are on most Thursdays. We will resume regular Thursday office hours (8:00 AM to 6:00 PM) on September 15th. Thank you for your understanding!
- June 5th is National Cancer Survivors Day
- August is National Breastfeeding Month
- August 1-7 is World Breastfeeding Week
- September is Ovarian Cancer Awareness Month
Endometriosis: It Really is a Pain!
Endometriosis is the most common cause of chronic pelvic pain, affecting more than 6%-10% of US women of reproductive age or 4-6 million women, according an article published in Fertility and Sterility. Endometriosis is typically treated with medications such as Lupron, which has an array of negative side effects, or with a surgical procedure known as a laparoscopy. A recent study evaluated the use of a medication called Femara for refractory endometriosis-related chronic pelvic pain. They looked at 16 patients and found that individuals who used Femara for 180 +/- 31 days reduced their pain level from a 7 on a 0-10 pain scale to a 1.5. These patients were also placed on a progestin or oral contraceptive to lessen side effects such as hot flashes and bone loss. All patients in this study had already failed at least two types of therapy. The most common cited side effects were weight gain, hot flashes, ovarian cyst development, fatigue, and breakthrough vaginal bleeding. The majority of patients who initiated treatment continued through the recommended 6-month course, and treatment was generally well tolerated. We have been using this treatment here at the Southeastern Center for Fertility and Reproductive Surgery for years now, and have had similar results. New therapies are also available, so if you are still suffering from Endometriosis, see us soon!
Honey! I Shrunk the...Endometrioma?!
An endometrioma is a type of ovarian cyst that is caused by endometriosis, which is where the uterine lining deposits on organs inside the pelvis. Cabergoline (Dostinex) is a medication used to decrease high prolactin levels: a condition known as hyperprolactinemia; however, Dostinex has also been used "off-label" in the treatment of endometriosis/endometriomas. A 2014 study published in General Gynecology looked at 140 patients with known endometriomas to determine whether shrinkage of the endometriomas was better achieved with the standard therapy of a luteinizing hormone releasing hormone (LHRH) agonist, Triptorelin Acetate (Decapeptyl), or with Dostinex. Group I comprised 71 patients who all received Dostinex 0.5 mg twice weekly for 12 weeks. Group II comprised 69 patients who all received Decapeptyl 3.75 mg subcutaneously once a month for 3 months. All patients underwent vaginal ultrasound before and after the treatment period to compare the change in endometrioma size. In Group I, 46 out of the 71 patients (64.7%) had a significant (>25%) decrease in endometrioma size. In Group II, 15 out of 69 patients (21.7%) had a significant decrease in endometrioma size. In conclusion, Dostinex yields better results in reduction of endometrioma size. It has no major side effects, is easier to administer, and is cheaper than LHRH agonists.